Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Aberrant protein phosphorylation is a critical driver of cancer development and progression.
• Understanding kinase-substrate interactions is essential for deciphering cancer signaling networks.

Purpose of the Study:

• To comprehensively map kinase-substrate regulation across diverse breast cancer subtypes.
• To identify master regulators of phosphorylation and potential therapeutic targets.

Main Methods:

• Quantitative phosphoproteomics analysis of 77 breast tumors and 24 xenografts.
• Identification and correlation of kinase-phosphosite pairs.
• Bioinformatic analysis to predict kinase activity and identify druggable targets.

Main Results:

• Discovered 2134 kinase-phosphosite pairs, extending existing knowledge.
• Identified subtype-specific kinase signaling (e.g., EGFR, ERBB2, PRKG1, WNK1).
• Revealed CDKs, MAPKs, and ataxia-telangiectasia proteins as dominant regulators.
• Unveiled 113 kinase-substrate pairs and downstream cascades as potential druggable targets.
• Linked kinase-substrate pairs to clinical and immune signatures.
• Experimentally validated key activated phosphosites (ERBB2, EIF4EBP1, EGFR).

Conclusions:

• Kinase-substrate regulation provides a deeper understanding of cancer signaling than genomic data alone.
• This extensive phosphoproteomic map connects driver events to signaling effects and identifies therapeutic opportunities.